All filters
Slidesets
Transmisión de mutaciones de resistencias a inhibidores de la integrasa- I. Viciana
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Reduced drug regimens, what’s the magic number: three, two or one? – Overview- Jonathan Schapiro, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Pharmacological perspective- José Moltó, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Toxicity and co-morbidities perspective- José Ignacio Bernardino, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Virological perspective- Santiago Moreno, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
HIV Prevention 2.0- Charles Boucher, MD, PhD
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. Santos
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir and lamivudine as dual maintenance therapy- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Reasons for discontinuation of dual therapy with dolutegravir and riplivirine- R. Montejano
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice- V. Moreno-Torres
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Experiencia con Inhibidores de la Integrasa en un hospital terciario- I. Mur
Presented at:
Spanish HIV Clinical Forum 2017
Slidesets
Opening lecture: A pathologist, a radiologist and a hepatologist walked into a bar- Brent Neuschwander-Tetri, MD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Innovation in histological assessment of NASH- Pierre Bedossa, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
EU perspective- Elmer Schabel, MD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Session 2: Pathways to biomarker qualification and acceptance- Chris Leptak, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Collaboration in action - Foundation for the National Institutes of Health- Roberto Calle, MD, FACE, FACP
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Collaboration in action - Innovative Medicines Initiative- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Circulating nucleic acids and combination panels- Sven Francque, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
MRI; what can it deliver- Claude Sirlin, MD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Role of genetic assessments- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steatohepatitis clinical trial- Michael Middleton
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
A meta-analysis on repeatability of magnetic resonance elastography of liver- Suraj Serai
Presented at:
International Workshop on NASH Biomarkers 2017